Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Efficacy of a Synthetic Vaccine Derived From Plasmodium Vivax Circumsporozoite Protein (PvCS) in naïve and Semi-immune Volunteers

25 februari 2021 uppdaterad av: Malaria Vaccine and Drug Development Center

Safety and Protective Efficacy of a Synthetic Vaccine Derived From the CS Protein of Plasmodium Vivax: a Double-blind, Placebo-controlled, Randomized Clinical Trial in naïve and Pre-immune Colombian Volunteers

This is a randomized, double-blind, controlled, which seeks to compare two groups of volunteers (naive and previously exposed to malaria) vaccinated with three doses of a synthetic derivative of the CS protein of Plasmodium vivax to determine their protective efficacy.

Then volunteers will be subject to an infectious challenge (Controlled Human Malaria Infection) to assess the infectivity of gametocytes in the blood early stage of P. vivax in Anopheles albimanus mosquitoes.

Studieöversikt

Status

Har inte rekryterat ännu

Betingelser

Detaljerad beskrivning

This study is a prospective controlled, blinded clinical trial, designed to establish the protective efficacy induced by the vaccine PvCSP between human volunteers with and without history of malaria. Volunteers will be recruited in Cali, Colombia and Quibdó, Colombia.

Study subjects: This study will require the involvement of two types of volunteers, parasite donors and volunteers for immunization

Parasite donors: 5-15 P. vivax-infected patients who will serve as parasites donors for experimental infection of mosquitoes, who will be enrolled in the endemic area.

Volunteers for immunization: Two other groups of volunteers will be immunized with the PvCSP vaccine. A group of 60 people without previous exposure to malaria (naïve) and another 60 people with a history of previous malaria infection (pre-immune).

Methodology Recruitment of infected patients: Parasite donors will be recruited among P. vivax infected patients attending a diagnostic center in the endemic area.

Infection of mosquito's blood from donors will be used to feed three-day-old mosquitoes by artificial membrane feeding technique. At day 7, a sample of mosquitoes will be examined to determine the level of infection by dissection of the mosquito's gut. On day 14, a small number of mosquitoes with a good degree of infectivity will be used to infect challenged volunteers.

Recruitment of pre-immune and naive volunteers: Volunteers for the immunization stage will be recruited both in the city of Cali (Colombia), non-endemic region, and in Quibdó (Colombia), a malaria endemic region, through various activities such as conferences, meetings and other strategies previously approved by the IRB, like posters, radio advertising flyers and social media.

Immunization: Volunteers will be immunized with the vaccine (n=60) or placebo (n=60).

Follow-up of volunteers will be performed under medical vigilance during the first hour following the immunization to detect any adverse reaction. After the first hour period a medical exam will be made. Eight hours after immunization, each volunteer will be contacted via telephone to assess physical condition. Any adverse event (AE) will be registered.

Subsequent follow up will be made on the day next to immunization and 1 or 2 weeks before the next immunization by a new clinical evaluation and AE report. Volunteers will be instructed to contact the research staff at any moment.

Infection of volunteers immunized volunteers will be challenged on day ~150 of the study, 1 month after the third immunization by the bite of 2-4 infected mosquito. A "feeding cage" will be placed on the forearm of a volunteer for 10 minutes, allowing that the feeding window, which will be covered by a mesh surface be placed against the volunteer's skin.

Volunteers will be instructed about the signs and symptoms of malaria and they will have a daily telephone contact during the first 6 days.

Between days 7 and 23 the volunteers will be asked to go to the Clinical Trials Unit daily to establish the presence or absence of disease through thick blood smear and samples will be collected for retrospective real time PCR P. vivax.

From day 23 until day 31, volunteers will receive physical and laboratory evaluation every other day and will have daily telephone contact.

Once the patients present signs and symptoms of the disease curative treatment will be immediately provided, and 15 ml of blood will be drawn, which will be used for immune response assessment.

If the volunteers do not develop the disease during the follow-up period, on day 31 they will be given antimalarial treatment.

Treatment Volunteers will be treated with antimalarial drugs approved by the Colombian Ministry of Social Health: chloroquine (three (3) doses: 600 mg initially, followed by 450 mg at 24, and 48 hours), associated with primaquine (30mg/day) for 14 days. All the volunteers will be asked to return two weeks after starting treatment for a thick blood smear test to ensure cure of malaria.

Studietyp

Interventionell

Inskrivning (Förväntat)

120

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Valle Del Cauca
      • Cali, Valle Del Cauca, Colombia
        • Malaria Vaccine and Drug Development Center
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 45 år (Vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

Naïve group:

  1. Non-pregnant, healthy men and women between 18-45 years old.
  2. Freely and voluntarily sign an IC, accompanied by two witnesses who must also sign.
  3. Absence history of malaria infection.
  4. To have negative serology for the PvCS protein by the ELISA test.
  5. For women, not be pregnant.
  6. Use of an adequate contraceptive method from the beginning until the contraceptive restriction is lifted by a study doctor, at the end of the study.
  7. To accept not to travel to areas considered as endemic for malaria from the infectious challenge period and to the end of its follow-up (1 month).
  8. Be reachable by phone throughout the study period.
  9. To be Duffy positive (Fy +).
  10. Have Hemoglobin (Hb) levels> 11 g / dl.
  11. Be willing to participate during the period in which the study will take place.
  12. Not be participating in another clinical study.
  13. Be affiliated with the general health social security system of Colombia, in any of its regimes (subsidized or contributory)

Semi-immune group:

  1. Non-pregnant, healthy men and women between 18-45 years old,
  2. Freely and voluntarily sign an informed consent, accompanied by two witnesses who will also sign.
  3. Have a history of malaria infection (s) and positive serological tests (ELISA) for P. vivax.
  4. For women, not be pregnant or nursing.
  5. For women, use of adequate contraception from inception until the contraceptive restriction is lifted by a study physician.
  6. Be a permanent resident of the municipality of Quibdó during the study.
  7. Be reachable by phone throughout the study period.
  8. Availability to participate during the period in which the study will take place.
  9. Be affiliated with the general health social security system of Colombia, in any of its regimes (subsidized or contributory)

Exclusion Criteria:

Naïve group:

  1. Glucose 6 phosphate dehydrogenase deficiency (G-6-P-D).
  2. Present any hemoglobinopathy (eg HbS).
  3. Personal history of allergies to medications or insect bites.
  4. Have received vaccination against malaria.
  5. Clinical or laboratory abnormalities determined by the investigator (s).
  6. IFAT> 1:20 for P. vivax in screening tests.
  7. Have lived in a malaria-endemic region during the 12 months before the study.
  8. Clinical or laboratory evidence of systemic disease, including kidney, liver, cardiovascular, pulmonary, psychiatric, or other diseases that may negatively impact and alter study results.
  9. Evidence of active hepatitis B or Hepatitis C infection
  10. Evidence of active HIV infection.
  11. History of transfusion of any blood product in the 6 (six) months before the study.
  12. Plan to have surgery from the recruitment period to the end of the post-challenge follow-ups.
  13. Presence or history of autoimmune disease (lupus, rheumatoid arthritis, thyroiditis, or other).
  14. Splenectomized volunteers.
  15. Volunteers in treatment with drugs with activity on the immune system (steroids, immunosuppressive agents, or immunomodulators).
  16. History of alcoholism or drug abuse defined as a habit that interferes with the normal social functioning of the individual.
  17. Any condition that may interfere with the ability to provide a free and voluntary IC.
  18. Not being affiliated with the general health social security system of Colombia, in any of its regimes (subsidized or contributory)

Semi-immune group:

  1. IFAT negative (<1:20) for P. vivax in screening tests.
  2. The other criteria used in the case of naïve volunteers, except the antecedent of having lived in the endemic area.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Förebyggande
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Arm N Vaccine
30 malaria-naïve subjects from non-endemic areas of Cali, Colombia.
Vaccine PvCS N+C+R 150 mcg (Montanide ISA-51), freeze dried powder.
Placebo-jämförare: Arm N Placebo
30 malaria-naïve subjects from non-endemic areas of Cali, Colombia.
SSN Montanide ISA-51 1 mL
Experimentell: Arm S Vaccine
30 semi-immune subjects from malaria endemic areas of Chocó, Colombia.
Vaccine PvCS N+C+R 150 mcg (Montanide ISA-51), freeze dried powder.
Placebo-jämförare: Arm S Placebo
30 semi-immune subjects from malaria endemic areas of Chocó, Colombia.
SSN Montanide ISA-51 1 mL

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Frequency of first case of P. vivax malaria after CHMI and meeting the primary case definition.
Tidsram: Assessed over average of 16-18 days post CHMI (range 7 to 60 days)
The first case of malaria meeting the primary case definition will be defined as the first or only episodes with the presence of Plasmodium vivax parasitemia ≥ 0.1% by thick blood smear and malaria qPCR.
Assessed over average of 16-18 days post CHMI (range 7 to 60 days)

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Concentration of specific anti-PvCS IgG antibodies IgG (isotypes) against the different functional fragments of the Pv-CS protein.
Tidsram: Days 0, 30, 60, 90, 120, 180, 210 and 240.

Concentration of specific anti-PvCS IgG antibodies IgG (isotypes) against the different functional fragments of the Pv-CS protein (Amino, Central Repeat and Carboxilo terminal). Expressed both as antibody titers and Reactive Indices (RI) measured by in enzyme-linked immunosorbent assay (ELISA) and Immunofluorescence Test (IFAT). Antibody titers by IFAT are determine as the reciprocal of the end-points dilution showing a positive fluorescence.

Concentrations will be presented as geometric mean concentrations (GMCs).

Days 0, 30, 60, 90, 120, 180, 210 and 240.
Specific cytokine induction
Tidsram: Days 0, 30, 60, 90, 120, 180, 210 and 240.
Specific cytokine induction will be measured by IFN- γ, TNF-α, IL-2; IL- 4, IL-6, IL-10
Days 0, 30, 60, 90, 120, 180, 210 and 240.
T-cell response measurement - Flow cytometry
Tidsram: Days 0, 30, 60, 90, 120, 180, 210 and 240.
In vitro proliferation of CD3+ T-cells (CD4+ and CD8+) and intracellular production of cytokines IFN-gamma, TNF-a, IL-12 by flow cytometry. Result will be expressed as percentages.
Days 0, 30, 60, 90, 120, 180, 210 and 240.
T-cell response measurement - ELIspot
Tidsram: Days 0, 30, 60, 90, 120, 180, 210 and 240.
Production of IFN-gamma and IL-10 in total PBMC stimulated with the different antigens and / or synthetic peptides by ELIspot assay. Results expressed as the mean number of IFN-γ spot-forming cells (sfc) per 106 Peripheral Blood Mononuclear Cells.
Days 0, 30, 60, 90, 120, 180, 210 and 240.
T-cell response measurement - Bioplex
Tidsram: Days 0, 30, 60, 90, 120, 180, 210 and 240.
Multiplex cytokines profile (Th1/Th2/Treg) in sera by bioplex. Cytokine concentrations were calculated from the standard curve using seven-parameter curve fitting software and the results were expressed in pg/mL. The limit of detection for the assay was 10 pg/mL for all cytokines. Results will be expressed as percentages.
Days 0, 30, 60, 90, 120, 180, 210 and 240.
Characterization of T lymphocytes
Tidsram: Days 0, 30, 60, 90, 120, 180, 210 and 240.
Phenotyping and profiles of memory T lymphocytes will be done in PBMCs using specific panels of markers by flow cytometry. The frequency of cells as a biomarker post CHMI infection will be performed. Cells will be stained by using different antibody cocktails targeting specific cell populations. Cells acquisition will be done on a 4-laser BD flow cytometer and gating analysis with FlowJo software version 10.4.2. Results will be expressed as percentages.
Days 0, 30, 60, 90, 120, 180, 210 and 240.
Characterization of B lymphocytes.
Tidsram: Days 0, 30, 60, 90, 120, 180, 210 and 240
Phenotyping and profiles of B lymphocytes will be done in PBMCs using specific panels of markers by flow cytometry. The frequency of cells as a biomarker post CHMI infection will be performed. Cells will be stained by using different antibody cocktails targeting specific cell populations. Cells acquisition will be done on a 4-laser BD flow cytometer and gating analysis with FlowJo software version 10.4.2. Results will be expressed as percentages.
Days 0, 30, 60, 90, 120, 180, 210 and 240
Characterization of monocytes
Tidsram: Days 0, 30, 60, 90, 120, 180, 210 and 240.
Phenotyping and profiles of monocytes will be done in PBMCs using specific panels of markers by flow cytometry. The frequency of cells as a biomarker post CHMI infection will be performed. Cells will be stained by using different antibody cocktails targeting specific cell populations. Cells acquisition will be done on a 4-laser BD flow cytometer and gating analysis with FlowJo software version 10.4.2. Results will be expressed as percentages.
Days 0, 30, 60, 90, 120, 180, 210 and 240.
Antibody functionality in vitro through inhibition of sporozoite invasion (ISI) to Hep-G2 cells.
Tidsram: Days 0, 30, 60, 90, 120, 180, 210 and 240.
Antibody functionality will be tested in vitro through essays of inhibition of sporozoite invasion (ISI) to Hep-G2 cells.
Days 0, 30, 60, 90, 120, 180, 210 and 240.
Vaccine-induced protection for P. vivax
Tidsram: Thirty days after mosquito bite challenge (Controlled Human Malaria Infection)
Vaccine-induced protection for P. vivax will be assessed by pre-patent period onset after infected mosquito bites exposure
Thirty days after mosquito bite challenge (Controlled Human Malaria Infection)
Multiomics testing (i.e., transcriptomics, genomics)
Tidsram: Days 0, 30, 90, 195 and 225.

Tthe present study also seeks to evaluate host-related variables, especially those affected by the immune status prior to vaccination (naïve vs pre-immune participants).

To accomplish this, transcriptomics and genomics tests will be undertaken on days 0, 30, 195 and, 225.

Days 0, 30, 90, 195 and 225.
Safety - Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Tidsram: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Assessed solicited local symptoms will be pain and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 swelling = swelling spreading beyond 20 millimeters (mm) of injection site.
During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Safety - Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Tidsram: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses

Assessed solicited general symptoms will be drowsiness, fever [defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)], irritability and loss of appetite.

Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity.

Grade 3 fever = fever higher than (>) 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Safety - Number of Subjects With Any Unsolicited Adverse Events (AEs)
Tidsram: Within the 30-day (Days 0-29) post-vaccination follow-up period

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

Any will be defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

Within the 30-day (Days 0-29) post-vaccination follow-up period
Safety - Number of Subjects With Serious Adverse Events (SAEs)
Tidsram: Throughout the study period (Day 0 - Month 14)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Throughout the study period (Day 0 - Month 14)
Safety - Number of Subjects With Hemoglobin Values Outside Normal Ranges With Toxicity Grades
Tidsram: Days 0, 30, 60, 90, 120, 180, 210 and 240.
Toxicity levels will be measured according to the Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0.
Days 0, 30, 60, 90, 120, 180, 210 and 240.
Safety - Number of Subjects With White Blood Cell (WBC) Values Outside Normal Ranges With Toxicity Grades
Tidsram: Days 0, 30, 60, 90, 120, 180, 210 and 240.
Toxicity levels will be measured according to the Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0.
Days 0, 30, 60, 90, 120, 180, 210 and 240.
Safety - Number of Subjects With Platelet Values Outside Normal Ranges With Toxicity Grades
Tidsram: Days 0, 30, 60, 90, 120, 180, 210 and 240.
Toxicity levels will be measured according to the Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0.
Days 0, 30, 60, 90, 120, 180, 210 and 240.
Safety - Number of Subjects With Alanine Aminotransferase (ALT) Values Outside Normal Ranges With Toxicity Grades
Tidsram: Days 0, 30, 60, 90, 120, 180, 210 and 240.
Toxicity levels will be measured according to the Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0.
Days 0, 30, 60, 90, 120, 180, 210 and 240.
Safety - Number of Subjects With Creatinine Values Outside Normal Ranges With Toxicity Grades
Tidsram: Days 0, 30, 60, 90, 120, 180, 210 and 240.
Toxicity levels will be measured according to the Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0.
Days 0, 30, 60, 90, 120, 180, 210 and 240.
Safety - Number of Subjects With Bilirubin Values Outside Normal Ranges With Toxicity Grades
Tidsram: Days 0, 30, 60, 90, 120, 180, 210 and 240.
Toxicity levels will be measured according to the Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0.
Days 0, 30, 60, 90, 120, 180, 210 and 240.
Safety - Number of Subjects With Alkaline phosphatase Values Outside Normal Ranges With Toxicity
Tidsram: Days 0, 30, 60, 90, 120, 180, 210 and 240.
Toxicity levels will be measured according to the Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0.
Days 0, 30, 60, 90, 120, 180, 210 and 240.
Safety - Number of Subjects With Blood urea nitrogen (BUN) Values Outside Normal Ranges With Toxicity
Tidsram: Days 0, 30, 60, 90, 120, 180, 210 and 240.
Toxicity levels will be measured according to the Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0.
Days 0, 30, 60, 90, 120, 180, 210 and 240.
Safety - Number of Subjects With Aspartate aminotransferase (AST) Values Outside Normal Ranges With Toxicity
Tidsram: Days 0, 30, 60, 90, 120, 180, 210 and 240.
Toxicity levels will be measured according to the Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0.
Days 0, 30, 60, 90, 120, 180, 210 and 240.
Safety - Number of Subjects With Prothrombin time (PT)) Values Outside Normal Ranges With Toxicity
Tidsram: Days 0, 30, 60, 90, 120, 180, 210 and 240.
Toxicity levels will be measured according to the Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0.
Days 0, 30, 60, 90, 120, 180, 210 and 240.
Safety - Number of Subjects With Partial thromboplastin time (PTT) Values Outside Normal Ranges With Toxicity
Tidsram: Days 0, 30, 60, 90, 120, 180, 210 and 240.
Toxicity levels will be measured according to the Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0.
Days 0, 30, 60, 90, 120, 180, 210 and 240.
Safety - Number of participants with confirmed pregnancy
Tidsram: Days 0, 30, 60, 90, 120, 180, 210 and 240.
Number of participants with confirmed pregnancy during the study duration.
Days 0, 30, 60, 90, 120, 180, 210 and 240.
Safety - Glucose-6-phosphate dehydrogenase deficiency
Tidsram: Day 0.
Glucose-6-phosphate dehydrogenase deficiency test will be done during baseline evaluation.
Day 0.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Socrates Herrera, MD, Director

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Förväntat)

1 juni 2021

Primärt slutförande (Förväntat)

1 juni 2022

Avslutad studie (Förväntat)

1 december 2022

Studieregistreringsdatum

Först inskickad

25 januari 2021

Först inskickad som uppfyllde QC-kriterierna

1 februari 2021

Första postat (Faktisk)

5 februari 2021

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

1 mars 2021

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

25 februari 2021

Senast verifierad

1 februari 2021

Mer information

Termer relaterade till denna studie

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera